Table 1.
Characteristics of Patients Who Received Ceftolozane/Tazobactam and Those Who Received the Standard of Care
| Characteristic | Ceftolozane/Tazobactam (n = 47) |
Standard of Care (n = 50) |
P Value |
|---|---|---|---|
| Age, y, median (range) | 60 (25–84) | 55 (18–79) | .12 |
| Sex | .65 | ||
| Male | 28 (60) | 32 (64) | |
| Female | 19 (40) | 18 (36) | |
| Race/ethnicity | .85 | ||
| White | 32 (68) | 35 (70) | |
| Black | 4 (9) | 5 (10) | |
| Hispanic | 6 (13) | 7 (14) | |
| Asian | 0 (0) | 1 (2) | |
| Middle Eastern | 3 (6) | 1 (2) | |
| Other | 2 (4) | 1 (2) | |
| Hematological malignancy | .32 | ||
| ALL | 9 (19) | 12 (24) | |
| AML | 19 (40) | 22 (44) | |
| CML | 3 (6) | 0 | |
| Lymphoma | 9 (19) | 6 (12) | |
| Other | 7 (15) | 10 (20) | |
| BMT within 1 y prior to fever | 6 (13) | 9 (18) | .48 |
| Autologous | 2/6 (33) | 4/9 (44) | |
| Allogeneic | 4/6 (67) | 5/9 (56) | |
| Type of allogeneic transplant | |||
| Matched unrelated donor | 0 | 1/5 (20) | |
| HLA matched related donor | 4/4 (100) | 4/5 (80) | |
| GVHD | 1/6 (17) | 1/8 (13) | >.99 |
| Temperature at baseline, °C, median (IQR) | 37.3 (36.9–38.2) | 37.5 (37.0–38.3) | .31 |
| Temperature at initial presentation, °C | .32 | ||
| <36 | 0 | 0 | |
| 36–38 | 3 (6) | 7 (14) | |
| >38 | 44 (94) | 43 (86) | |
| Microbiological documentation (positivity) | 13 (28) | 12 (24) | .68 |
| Site of microorganism(s)a | |||
| Genitourinary tract | 2 | 1 | |
| Blood | 11 | 12 | |
| Gram-negative bacterial pathogen | 4 (9) | 2 (4) | .43 |
| Gram-negative alone | 2 | 2 | |
| Gram-negative and -positive (mixed infection) | 2 | 0 | |
| Organisms recovered in positive culturesb | |||
| Escherichia coli | 0 | 2 | |
| Klebsiella pneumoniae | 1 | 0 | |
| Pseudomonas aeruginosa | 1 | 0 | |
| MRSA | 2 | 1 | |
| Rothia mucilaginosa | 1 | 0 | |
| Streptococcus viridans | 5 | 5 | |
| Staphylococcus epidermidis | 1 | 2 | |
| Enterococcus faecalis | 0 | 2 | |
| E faecalis + E coli | 1 | 0 | |
| E faecalis + P aeruginosa | 1 | 0 | |
| CVC the source of BSI isolation | 7/11 (64) | 7/12 (58) | >.99 |
| Hospital stay duration, d, median (IQR) | 6 (4–9) | 7 (4–11) | .84 |
| ICU admission | 2 (4) | 3 (6) | >.99 |
| Mechanical ventilation | 2 (4) | 1 (2) | .61 |
Data are presented as No. of patients (%) unless otherwise indicated.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BMT, bone marrow transplantation; BSI, bloodstream infection; CML, chronic myeloid leukemia; CVC, central venous catheter; GVHD, graft-vs-host disease; HLA, human leukocyte antigen; ICU, intensive care unit; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus.
One patient had 2 sites of organisms.
Four patients had 2 or 3 organisms.